Results 11 to 20 of about 5,926 (192)

Cost-utility of talazoparib monotherapy treatment for locally advanced or metastatic breast cancer in Spain

Breast, 2021
Breast cancer is one of the most frequent malignancies. The aim of the article is to analyse the cost-utility ratio and budgetary impact of talazoparib treatment for patients with locally advanced or metastatic gBRCA + breast cancer from the perspective ...
Antonio Olry de Labry Lima, Zuzana Špacírová, Silvia Fénix-Caballero, Antonio Matas Hoces, Adrián Sánchez Vegas, Manuel Cárdenas Aranzana, Jesús F. Sierra-Sánchez, María del Carmen Martínez Díaz, Emilio Jesús Alegre del Rey   +8 more
doaj   +2 more sources

Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer [PDF]

Journal of Personalized Medicine, 2021
The use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors represents a potent strategy for cancer therapy. Due to the complex molecular network that regulates cell cycle progression, cancer cells often acquire resistance mechanisms against these inhibitors.
Florian G. Klein, Charlène Granier, Yuling Zhao, Qi Pan, Zhichao Tong, Jürgen E. Gschwend, Per Sonne Holm, Roman Nawroth   +7 more
openaire   +3 more sources

PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib

Scientific Reports, 2022
The synthetic lethal association between BRCA deficiency and poly (ADP-ribose) polymerase (PARP) inhibition supports PARP inhibitor (PARPi) clinical efficacy in BRCA-mutated tumors.
Xia Ding, Zhou Zhu, John Lapek, Elizabeth A. McMillan, Alexander Zhang, Chi-Yeh Chung, Sara Dubbury, Jennifer Lapira, Sarah Firdaus, Xiaolin Kang, Jingjin Gao, Jon Oyer, John Chionis, Robert A. Rollins, Lianjie Li, Sherry Niessen, Shubha Bagrodia, Lianglin Zhang, Todd VanArsdale   +18 more
doaj   +2 more sources

Talazoparib: First Global Approval

Drugs, 2018
Talazoparib (TALZENNA™) is an oral inhibitor of the polyadenosine 5'-diphosphoribose polymerase (PARP) enzymes, which play a critical role in repairing DNA single-strand breaks. It has been developed by Pfizer and was recently approved in the USA for the treatment of adults with deleterious or suspected deleterious germline BRCA-mutated, human ...
Güney Eskiler, Gamze, Guney Eskiler, G., Guney Eskiler G.   +2 more
core   +6 more sources

A Phase I Trial of Talazoparib in Patients with Advanced Hematologic Malignancies [PDF]

International Journal of Hematologic Oncology, 2021
The objective of this study was to establish the maximum tolerated dose (MTD), safety, pharmacokinetics, and anti-leukemic activity of talazoparib.This Phase I, two-cohort, dose-escalation trial evaluated talazoparib monotherapy in advanced hematologic malignancies (cohort 1: acute myeloid leukemia/myelodysplastic syndrome; cohort 2: chronic ...
Ajay K Gopal, Rakesh Popat, Ryan J Mattison, Tobias Menne, Adrian Bloor, Terry Gaymes, Asim Khwaja, Mark Juckett, Ying Chen, Matthew J Cotter, Ghulam J Mufti   +10 more
openaire   +4 more sources

Cost-effectiveness of talazoparib for patients with locally advanced or metastasized breast cancer in Germany.

PLoS ONE, 2022
This study evaluated factors that influence the cost-effectiveness of talazoparib, particularly for patients with a germline breast-cancer-gene-(brca)-mutation and locally advanced or metastasized breast cancer within the context of the German healthcare
Florian Schwarz, Habibollah Arefian, Michael Hartmann, Ingo Runnebaum   +3 more
doaj   +3 more sources

The clinically applied PARP inhibitor talazoparib ameliorates imiquimod-induced psoriasis in mice without reducing skin inflammation

Frontiers in Pharmacology
BackgroundConsidering the role PARPs play in inflammation, we assessed the effect of PARP inhibition in an inflammatory skin condition, psoriasis, to explore novel avenues for the potential repurposing of PARP inhibitors that are currently used in tumour
Petra Molnár, Máté Ágoston Demény, Beáta Várkonyi, Beáta Várkonyi, Zsuzsanna Polgár, Ágnes Pór, Ilona Kovács, Andrea Szegedi, Andrea Szegedi, Attila Gábor Szöllősi, Attila Gábor Szöllősi, Magdolna Szántó   +11 more
doaj   +2 more sources

Abstract 3100: Nanoformulated Talazoparib and Olaparib for enhanced delivery

Cancer Research, 2017
Abstract Introduction: PARP inhibitors such as Talazoparib and Olaparib exploit deficiencies in DNA repair pathways, making them attractive candidates for treatment of a number of different cancers. These drugs are particularly effective when used in combination with other DNA damaging agents such as chemotherapeutics and radiation ...
Paige Baldwin, Rajiv Kumar, Edward Favours, Karen Liby, Raushan Kurmasheva, David Kozono, Srinivas Sridhar   +6 more
core   +3 more sources

Talazoparib Bests Chemo for Breast Cancer

Cancer Discovery, 2018
Abstract Patients with advanced or metastatic HER2-negative breast cancer and germline BRCA1/2 mutations may benefit from talazoparib, according to data from a phase III trial. Compared with chemotherapy, the investigational PARP inhibitor induced some complete responses, prolonged progression-free survival, and improved patients ...
openaire   +3 more sources

Pharmacokinetic Drug-Drug Interaction Potential of Oral Anticancer Drugs. [PDF]

Clin Pharmacol Ther
Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Alhurayri F, Younis IR, Jalal SI, Logan TF, Maniar R, Bray SM, Quinney SK, Desta Z, Skaar TC, Tisdale JE, Shugg T.   +10 more
europepmc   +2 more sources